Business
Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics
IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management
About this update from Beta Bionics, Inc.
[{"type":"text","content":"IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025. Members of the Company’s management team will host in-person meetings in San Francisco, CA from January 12, 2026 through January 14, 2026 to discuss preliminary topline fourth quarter 2025 financial results and key metrics set forth below. The Company invites investors to register for in-person meetings by contacting the Company’s investor relations representative at [email protected]. Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results & Key Metrics Net sales expected to be at least $32.0 million, up at least 56% compared to $20.4 million in the fourth quarter of 2024. Durable Medical Equipment (DME) channel net sales expected to be at least $22.3 million, up at least 23% compared to $18.1 million in the fourth quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales expected to be at least $9.7 million, up at least 308% compared to $2.4 million in the fourth quarter of 2024. Installed customer base (calculated as all new patient starts over a rolling four-year period) expected to be at least 35,000 users, up at least 128% compared to 15,298 in the fourth quarter of 2024.New patient starts expected to be at least 5,581, up at least 36% compared to 4,084 new patient starts in the fourth quarter of 2024. Approximately 69% of new patient starts expected to have come from multiple daily injections (MDI).Approximately a low-30s percentage of new patient starts expected to be reimbursed through the PBP channel, increasing relative to the prior quarter.Approximately 25-30% of new patient starts expected to be people with type 2 diabetes, increasing relative to the prior quarter. Fourth Quarter and Full Year 2025 Financial Results and Conference Call Beta Bionics plans to report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026 after the close of market. Management will host a conference call and concurrent webcast that day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the Company’s fourth quarter and full year 2025 performance. More details will be provided at a later date. Abou...